Becton Dickinson and Co (BDX) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $2.35 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.15. Analysts had a consensus of $2.20. The company posted revenue of $3198.00 million in the period, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .
Becton Dickinson and Co closed down -0.35 points or -0.20% at $176.43 with 7,28,257 shares getting traded on Tusday. Post opening the session at $176.38, the shares hit an intraday low of $174.88 and an intraday high of $176.6 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.
In a different news, on Jun 14, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,931 shares at $169.87 per share price. According to the SEC, on Jun 8, 2016, Nabil Shabshab (Executive Vice President) sold 5,080 shares at $168.75 per share price. On May 18, 2016, Jeffrey S Sherman (Sr. VP and General Counsel) sold 34,373 shares at $166.27 per share price, according to the Form-4 filing with the securities and exchange commission.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.